Literature DB >> 15383733

Pitfalls in the imaging diagnosis of hepatocellular nodules in the cirrhotic and noncirrhotic liver.

Kengo Yoshimitsu1, Hiroyuki Irie, Hitoshi Aibe, Tsuyoshi Tajima, Akihiro Nishie, Yoshiki Asayama, Kunishige Matake, Tomohiro Nakayamka, Daisuke Kakihara, Hiroshi Honda.   

Abstract

Contrast-enhanced CT and MR are the most commonly used modalities for objective evaluation of hepatocellular nodules. Various types of pseudolesions as seen on CT or MR have been reported, which are attributable to either focal alteration in hemodynamics or parenchymal metabolism, or to both. Pseudolesions specifically seen in cirrhotic liver include arterio-portal shunt, regenerating or hyperplastic nodules, and confluent fibrosis. In noncirrhotic liver, transient focal compression to the liver, third inflow other than normal hepatic arterial and portal venous flow, and vessel compromise are the causes of pseudolesions. To understand the characteristic features of these pseudolesions, and their underlying mechanism as well, is important for proper diagnosis of true hepatocellular lesions. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2004        PMID: 15383733     DOI: 10.1159/000078476

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  3 in total

1.  Dynamic changes in ultrasound characteristics of nodules in cirrhotic liver and their implications in surveillance for malignancy.

Authors:  Size Wu; Rong Tu; Guangqing Liu; Yusen Shi
Journal:  J Med Ultrason (2001)       Date:  2013-09-03       Impact factor: 1.314

2.  Confluent hepatic fibrosis in liver cirrhosis: possible relation with middle hepatic venous drainage.

Authors:  Kumi Ozaki; Osamu Matsui; Toshifumi Gabata; Satoshi Kobayashi; Wataru Koda; Tetsuya Minami
Journal:  Jpn J Radiol       Date:  2013-06-06       Impact factor: 2.374

Review 3.  Multistep human hepatocarcinogenesis: correlation of imaging with pathology.

Authors:  Masatoshi Kudo
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.